The Behavioural Effects and Sept-Hippocampal Cholinergic Activity Changes Caused by Repeated Bont/A Injection on Facial Muscle in Adolescent Mice

Xinxin Xu,Linhui Ni,Di Sun,Hanze Chen,Qiwen Tang,Shuxia Cao,Xingyue Hu
DOI: https://doi.org/10.2139/ssrn.4071594
2022-01-01
SSRN Electronic Journal
Abstract:Botulinum neurotoxin type A (BoNT/A) is a potent metalloprotease that acts primarily by specifically cleavage of presynaptic synaptosomal-associated 25 kDa (SNAP-25), consequently blocking the release of neurotransmitters such as acetylcholine (ACh) at the neuromuscular junction and autonomic innervations of glands and smooth muscles. Long-term and repeated application of BoNT/A is the therapeutic basis for diseases such as dystonia, muscle spasms and so on. Accumulating evidence suggested that toxin can be retrograde axonal transported to the central nervous system (CNS) or indirectly affect somatosensory-motor cortical excitability and neuronal plasticity induced by altered proprioceptive signals from the periphery. However, the central effects of repeated BoNT/A injection on cognitive function as well as basal forebrain- hippocampal cholinergic signaling pathway remain unclear.Here, we investigated the long-term effect on cognitive performance through repeated doses of 10 U/kg BoNT/A facial injections in adult C57BL/6 mice. Using a range of behavioral paradigms including open field task, novel object recognition task, Y-maze and Morris water maze, we found that repeated facial application of BoNT/A did not impair motor coordination and cognitive performance. Even mice with repeatedly administered BoNT/A displayed enhanced working memory in Y-maze task; whereas the single BoNT/A treatment failed to improve the memory-related behaviors. Furthermore, the expression of choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) proteins in the hippocampus significantly increased following multiple BoNT/A injections. An immunofluorescence analysis demonstrated that the number of basal forebrain cholinergic neurons increased as the doses were increased. However, no changes in cholinergic levels were observed in the single BoNT/A-injection group. This study could inform safety considerations linked to BoNT/A in the clinic and contribute to the development of its widespread application in diverse diseases.
What problem does this paper attempt to address?